Cassava Sciences, Inc. SAVA saw its stock price soar Friday, possibly amid rising short interest and an anticipated conference call to discuss recent developments.
What To Know: The company’s short percent of float has risen by 23.21% since its last report, with 16.13 million shares sold short, accounting for 35.89% of the total float. It would take traders an average of 4.75 days to cover their short positions based on the current trading volume.
What Else: Cassava Sciences is set to hold a conference call on Thursday August 8 2024, to discuss recent developments and provide a company update. Analysts expect the company to report earnings per share (EPS) loss of $0.40.
Earlier this week, Cassava also announced plans to extend its open-label extension trials for simufilam by up to 36 months. This will allow patients from previous trials to continue their treatment while awaiting Phase 3 trial results.
SAVA Price Action: Cassava Sciences shares were up by 24.4% at $29.21 according to Benzinga Pro.
See Also:
Image: Courtesy of Cassava Sciences.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
